title: Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
abstract: There are very limited reports about childhood acute promyelocytic leukemia (APL), especially about arsenic trioxide (ATO) treatment in both induction and post-remission regimens. 35 newly diagnosed APL patients received ATO treatment in our center and the clinical course as well as the outcome of them was investigated. The dose of intravenous ATO was 0.15-0.17 mg/kg per day, only one patient got 0.33 mg/kg per day, maximum dose was 10 mg per day in induction therapy with minimal chemotherapy treatment (CT) for hyperleukocytosis. Anthracycline or anthracycline-based CT was used for consolidation therapy and followed by 0.10-0.15 mg/kg per day ATO treatment in maintenance therapy. The continuous detection for morphology of bone marrow and PML-RARa were necessary for administrating CT or not. 3 patients died during induction therapy for intracranial hemorrhage, leukocytosis and septic shock. Total of 30 patients achieved complete remission (CR) and were followed-up for 10-108 months. The overall survival (OS) for all patients was 82.7%, whereas the OS for patients obtained CR was 95.8%. The event-free survival for 5 years was 80.3%. Disseminated intravascular coagulation could be under control to reduce induction mortality with adequate supportive care, especially in the first 2 weeks. The side effects of ATO were mild and transient. This regimen of ATO treatment both in induction and post-remission therapy was effective and safe for childhood APL to get long-term survival.
authors.affiliation: Pediatric Hematology/Oncology Department, Hematology Center, ShengJing Hospital of China Medical University, Sanhao Street #36, Heping District, Shenyang, 110004, Liaoning, China. wang_hong354@hotmail.com
authors.forename: Hong
authors.initials: H
authors.lastname: Wang
authors.forename: Liangchun
authors.initials: L
authors.lastname: Hao
authors.forename: Xiuli
authors.initials: X
authors.lastname: Wang
authors.forename: Jiate
authors.initials: J
authors.lastname: Li
authors.forename: Qiong
authors.initials: Q
authors.lastname: Wu
authors.forename: Shuang
authors.initials: S
authors.lastname: Bian
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D004211:Disseminated Intravascular Coagulation / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide
references.citation: Leuk Res. 2007 Jun;31(6):765-71
references.pmid: 17007927
references.citation: Blood. 2005 Jul 15;106(2):447-53
references.pmid: 15677559
references.citation: Hematology Am Soc Hematol Educ Program. 2008;:391-9
references.pmid: 19074116
references.citation: J Clin Oncol. 2004 Apr 15;22(8):1404-12
references.pmid: 15084614
references.citation: Pediatr Blood Cancer. 2008 Aug;51(2):210-5
references.pmid: 18428427
references.citation: Hematology Am Soc Hematol Educ Program. 2003;:82-101
references.pmid: 14633778
references.citation: Blood. 1999 Nov 15;94(10):3315-24
references.pmid: 10552940
references.citation: Blood. 2001 Sep 1;98(5):1633; author reply 1633-4
references.pmid: 11547772
references.citation: Blood. 2002 Dec 15;100(13):4298-302
references.pmid: 12393590
references.citation: Leukemia. 2004 Oct;18(10):1587-90
references.pmid: 15356649
references.citation: Blood. 2008 Mar 1;111(5):2505-15
references.pmid: 18299451
references.citation: Eur J Haematol. 2009 Nov;83(5):391-405
references.pmid: 19563518
references.citation: Blood. 2008 Jan 15;111(2):566-73
references.pmid: 17959855
references.citation: Blood. 2006 Apr 1;107(7):2627-32
references.pmid: 16352810
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7632-40
references.pmid: 16234524
references.citation: Science. 2010 Apr 9;328(5975):240-3
references.pmid: 20378816
references.citation: Blood. 1981 Jun;57(6):1000-4
references.pmid: 6939451
references.citation: Semin Thromb Hemost. 2007 Jun;33(4):330-8
references.pmid: 17525890
references.citation: Ann Oncol. 2006 Jan;17(1):131-4
references.pmid: 16227315
references.citation: Blood. 1996 Aug 1;88(3):1052-61
references.pmid: 8704214
references.citation: Blood. 1973 Apr;41(4):489-96
references.pmid: 4510926